GGrantIndex
Sort

40,608 grants matching prostate cancer

Curcuma Longa: epigenetic effects in prostate and colon cancer

$463,811
Ah-Ng Tony Kong · Rutgers, The State Univ Of N.J. · R01 · FY2016 · AT

Curcuma Longa: epigenetic effects in prostate and colon cancer

$463,811
Ah-Ng Tony Kong · Rutgers, The State Univ Of N.J. · R01 · FY2012 · AT

LHRH Synthetic Peptide Vaccine for Prostate Cancer

$463,803
United Biomedical, Inc. · R44 · FY2002 · CA

NYU COOPERATIVE PROSTATE CANCER TISSUE RESOURCE

$463,767
New York University School Of Medicine · U01 · FY2002 · CA

Ras-mediated signals in human epithelial cell transformation and metastasis

$463,709
Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies

$463,686
Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Agents for Specific NMR and SQUID Imaging of Prostate Cancer

$463,665
Laurel O Sillerud · University Of New Mexico · R01 · FY2010 · CA

Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards

$463,634
Gregory S Karczmar · University Of Chicago · R01 · FY2015 · CA

Prospective validation of a multi-marker prostate cancer prediction model

$463,618
Hans Gã–sta Lilja · Sloan-Kettering Inst Can Research · R01 · FY2013 · CA

Prostate-Specific Antigen Practices and Outcomes in the Elderly

$463,572
Louise C. Walter · Northern California Institute/Res/Edu · R01 · FY2009 · CA

STROMAL MODULATION BY THE SECRETORY FACTORS OF NEUROENDOCRINE-LIKE PROSTATE CANCER

$463,500
Virginia Commonwealth University · · FY2025 · Defense Health Agency

Targeting chemoresistant prostate cancer with novel EED inhibitors

$463,429
Daqing Wu · Clark Atlanta University · R01 · FY2023 · CA

Core C: Pathology, Biospecimen and Immune Profiling

$463,372
Tamara Levin Lotan · University Of Southern California · U19 · FY2022 · CA

Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation

$463,297
Emily Ho · Texas A&M University Health Science Ctr · P01 · FY2014 · CA

Measurement Errors in Cancer Epidemiology

$463,287
Donna L Spiegelman · Harvard School Of Public Health · R01 · FY2008 · CA

The origins of metabolic reprogramming in prostate cancer

$463,272
Andrew S Goldstein · University Of California Los Angeles · R01 · FY2019 · CA

Myosin VI: a new ubiquitin receptor

$463,245
Kylie Walters · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis

$463,166
Wei Yang · State University New York Stony Brook · R01 · FY2025 · CA

Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy

$463,165
James G Fujimoto · Massachusetts Institute Of Technology · R01 · FY2024 · CA

Human Leukemia Growth Inhibition by a Novel Retinoid

$463,144
Joseph A Fontana · Wayne State University · R01 · FY2008 · CA

Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer

$463,114
Kathryn L Penney · Brigham And Women'S Hospital · R37 · FY2021 · CA

Longevity and Medical Treatment in Old Age

$463,030
Sharon R Kaufman · University Of California, San Francisco · R01 · FY2011 · AG

Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis

$462,982
Cory Abate-Shen · Columbia University Health Sciences · P01 · FY2024 · CA

Molecular Targets for Cancer Detection and Treatment

$462,965
William George Nelson · Johns Hopkins University · T32 · FY2007 · CA

Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.

$462,850
Daniel Abate-Daga · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA